Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects - CRS. Experts. Early Phase.

Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

Science

ShareTwitter FacebookXingLinkedin

cytochrome P450 drug-drug interaction metabolism Nivasorexant pharmacokinetics selective orexin-1-receptor antagonist

You May Also Like

Science 16. November 2023

Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults

Science 25. Mai 2023

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Science 25. Mai 2023

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.